---
category: news
title: "Small Molecule Targeting CD47-SIRPα Pathway:..."
excerpt: "ISM004-1057D, Insilico's first PCC for its QPCTL program, is a potential first-in-class small molecule inhibitor that targets QPCTL. QPCTL is responsible for CD47 pyroglutamate formation, which is the modification essential for the interaction of CD47 with its ligand SIRPα."
publishedDateTime: 2022-02-17T07:30:00Z
originalUrl: "https://www.benzinga.com/pressreleases/22/02/n25681595/small-molecule-targeting-cd47-sirp-pathway-insilico-medicine-achieves-its-first-major-milestone-in"
webUrl: "https://www.benzinga.com/pressreleases/22/02/n25681595/small-molecule-targeting-cd47-sirp-pathway-insilico-medicine-achieves-its-first-major-milestone-in"
ampWebUrl: "https://www.benzinga.com/amp/content/25681595"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/25681595"
type: article
quality: 44
heat: 44
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.benzinga.com/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

secured: "2i+RCwMpJ0+pywOy2kfpqI2HTHmnS37Kscm5iHEgmK+3eq2EpLmUDNdj48AOt9RDo+YIpp4eRZIfvBDthzBELvI88+HiNSqlmO08n2Jp5zw0srbOTbJqJKB/kgQGSJ4iB4qmXGwUneOwHWPW7t+afrx2SfnE1hW+Xg0I9owJWzXeunhOmVT0GigVVCYUQj3pG3CRGZUVz6ATiDLQdS/ueRbzvYKLczZocdvQ3kJJyCQq4RwuSXKEyT+FiIU2iudd4qFa3e97h57I6RJEAhSqulMdmdLRu1mkmMVm/b6Fp6v+J6NVYRtCkF8XWi5IpIkfUBNaKW24bG8oylMLfdi4RiWOg1fsdT8L0UZ/UGSF2m8=;SpgSzr2pZg3NCTTidv4GvA=="
---

